Empatic

Bupropion/zonisamide

Combination of
Bupropion	Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Zonisamide	Sulfonamide anticonvulsant
Legal status
Legal status	Investigational

Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity. It is being developed by Orexigen Therapeutics. It is currently at phase II testing. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.

Empatic was called Excalia before its name was changed.

...
Wikipedia